Navigation Links
SDI Reports: Roughly Half of Patients Prescribed the Most Popular Osteoporosis Drugs Discontinue Therapy Within 6 Months -- Amgen's Prolia Offers New Dosing Option
Date:6/14/2010

According to SDI, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen’s Prolia is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months via injection.

(Vocus) June 14, 2010 -- According to a recent analysis by SDI, a leading healthcare market insight and analytics firm, about half of patients beginning therapy on popular osteoporosis drugs discontinue their treatment within 6 months. Amgen’s Prolia, which was recently approved for postmenopausal women with osteoporosis at high risk of fracture, or patients who could not tolerate other osteoporosis therapies, is the newest product to enter the market. Prolia differs from existing therapies as it is given every 6 months via injection.

Currently, alendronate, sometimes filled as Fosamax but more frequently as the generic equivalent, is the most popular treatment for osteoporosis. In the 12 months ending April 2010, alendronate accounted for almost 24% of drug issuances for the condition.

Generic alendronate is most often dispensed as a once-weekly therapy. SDI found that 49% of new alendronate patients had discontinued the drug 6 months later. Another 3% had switched to another therapy. After 12 months, 61% of new alendronate patients had discontinued therapy.    

The weekly form of Actonel had similar discontinuation rates. Fifty-four percent of patients taking Actonel once a week had discontinued therapy 6 months after starting; 64% had discontinued after 12 months.

The once-a-month version of Actonel fared slightly better after 6 months with only 47% of patients having discontinued therapy. But at 12 months, 63% had discontinued. The oral form of Boniva, also used once a month, had an even higher percentage of patients discontinuing therapy – 57% after 6 months and 70% after 12.

“Drug adherence is an issue that many in the healthcare industry struggle with, including physicians, pharmacies, and payers. If patients choose to discontinue therapy, they may be at a greater risk for progression of their disease or condition,” said SDI Chief Medical Officer Gregory Hess, M.D., M.B.A.. “There are financial ramifications as well. Using drug therapy to treat osteoporosis is less expensive than treating a patient with a broken bone because they didn’t adhere to therapy.”

About SDI:
SDI is a leading healthcare market insight and analytics firm. It provides the industry’s most comprehensive de-identified patient-level data to pharmaceutical, biotech, and medical device companies, enabling them to better understand the healthcare market. SDI also serves the government and the financial services, media, and consumer packaged goods industries. Founded in 1982, SDI counts the world’s top 50 pharmaceutical and biotech firms as its clients.

###

Read the full story at http://www.prweb.com/releases/2010/SDIosteoporosis/prweb4134214.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. SDI Reports: Pharmaceutical Promotion Spending Indicates Trend Toward Electronic and Online Promotion
2. SDI Reports: Hospital Outpatient Surgical Procedures Increasing, Surgery Centers Growing
3. SDI Reports: Emergency Room Visits Covered by Medicaid Increased 6% in 2009
4. SDI Reports: Nearly a Third Of Physicians Use Handheld and Smartphone Devices to Access Medical Information - Physicians Most Likely to be Using Apple iPhone
5. CNBC Presents 'Tom Brokaw Reports: BOOMER$!' on Thursday, March 4th at 9PM ET/PT
6. SIRIUS XM to Broadcast Doctor Radio Reports: Kids and Video Games - What You Should Know Before You Buy
7. Spinal cord stimulation may benefit Parkinsons patients
8. Brain MRI in children: Incidental findings yield disclosure dilemmas for doctors, patients
9. Study reveals causes of survival disparities based on insurance among rectal cancer patients
10. Uninsured more likely to die from trauma than patients with insurance, study finds
11. Intervention program helps breast cancer patients live longer after recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
SDI Reports: Roughly Half of Patients Prescribed the Most Popular Osteoporosis Drugs Discontinue Therapy Within 6 Months -- Amgen's Prolia Offers New Dosing Option
(Date:9/22/2017)... ... 22, 2017 , ... Pullano Law Offices, a Chicago personal injury law firm, ... selected to serve as President of the North Suburban Bar Association for 2017-2018. Mr. ... hosted by the NSBA at the North Shore Country Club in Glenview, IL, on ...
(Date:9/22/2017)... , ... September 22, 2017 , ... ... Rob Lowe, explores the world of Alzheimer’s. Alzheimer’s is a disease estimated to ... This according to information published by the Alzheimer’s Association, a leading voice in ...
(Date:9/22/2017)... ... September 22, 2017 , ... The freshly ... customers’ doorstep. According to Smart Mart, customers can now order vegetable, fruit, snacks, ... and customers can find clothing at discounted prices. Apart from this, Smart Mart ...
(Date:9/21/2017)... , ... September 21, 2017 , ... 38-Year-Old Plastic Surgeon ... Center in Naples, Florida is pleased to announce that Plastic Surgeon Kiranjeet Gill has ... 40 Under 40 is an annual award that was started in 2003 to ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... ... **An FDAnews Management Report**, http://www.fdanews.com/products/54818-promotional-communication      , In the competitive world of ... can get while staying in compliance with FDA rules. , The FDA has ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017 NeuroRx, a clinical stage ... Ideation and Behavior (ASIB), has been granted Fast Track status ... therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + ... pivotal trial of this sequential therapy targeting patients who are ... ...
(Date:9/5/2017)... Sept. 5, 2017  Just 18 months after its ... pleased to announce the appointment of three new senior ... , Dominic Jones-Phillips and James Wright ... Tammy Wynne ... market access writers. She has over ten years, experience ...
(Date:8/31/2017)... , Aug. 31, 2017 PM360,s ... must-read guide to the latest innovations happening across the ... industry publication to focus on providing a comprehensive look ... the issue covers the most innovative companies, startups, divisions, ... "Everyone in this industry ...
Breaking Medicine Technology: